EirGenix Company Description

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally.

The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services.

It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and currently under Phase I stage; EG13074, indicated for the treatment of cancer and currently under Preclinical stage; TSY0110(EG12043), an antibody-drug conjugate, indicated for the treatment of cancer and currently under Preclinical stage; EG12021, Bevacizumab biosimilar, indicated for the treatment of cancer and currently under Preclinical stage; and EG62054, a biosimilar, currently under Preclinical stage.

In addition, the company manufactures and sells covid-19 antigen rapid test; and EG74032, a CRM197 carrier protein.

The company was incorporated in 2012 and is headquartered in New Taipei City, Taiwan.

EirGenix Inc.

Country	Taiwan
Founded	2012
Industry	Biotechnology
Sector	Healthcare
CEO	Lee-Cheng Liu

Contact Details

Address: No. 101, Kangning Street New Taipei City Taiwan
Phone	886 2 7708 0123
Website	eirgenix.com

Stock Details

Ticker Symbol	6589
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
ISIN Number	TW0006589005
SIC Code	2836

Key Executives

Name	Position
Dr. Lee-Cheng Liu	Founder, President, Chief Executive Officer, CSO and Chairman
Hsiu-Chuan Yang	Chief Financial Officer, Vice President and Manager of Corporate Governance
Dr. Chih-Jung Chang	Vice President and Chief Operating Officer
Dr. Thomas Schulze Ph.D.	Managing Director of EirGenix Europe GmbH
Dr. Shang-Chung Ju	Executive Director and Chief Manufacturing Officer
Dr. Barbara Grohmann-Izay	Vice President and CMO